Bluebird Bio (NASDAQ: BLUE)
Bluebird Bio Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Bluebird Bio Company Info
Bluebird Bio is a development-stage biotechnology company focused on gene therapy, gene editing, and cancer immunotherapy.
News & Analysis
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.
Why Bluebird Bio Stock Flew Higher Than the Market Today
The company was thrown a financial lifeline.
Is Bluebird Bio Stock a Buy Now?
Are you feeling brave?
Why Bluebird Bio Stock Dived Into the Red on Tuesday
The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation.
If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today
The answer hardly inspires confidence.
2 Red Flags for Bluebird Bio Stock
The biotech's struggles may continue.
Better Risky Investment: Bluebird Bio vs. Shiba Inu
Few investors dare to tread where the ice is known to be very thin.
Should You Invest in Bluebird Bio Right Now?
After two December share price crashes, there's no evident cure for Bluebird Bio's ills.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.